AR027442A1 - Uso de una neurotoxina para preparar una composicion farmaceutica para el tratamiento de un desorden tiroide - Google Patents

Uso de una neurotoxina para preparar una composicion farmaceutica para el tratamiento de un desorden tiroide

Info

Publication number
AR027442A1
AR027442A1 ARP010100698A ARP010100698A AR027442A1 AR 027442 A1 AR027442 A1 AR 027442A1 AR P010100698 A ARP010100698 A AR P010100698A AR P010100698 A ARP010100698 A AR P010100698A AR 027442 A1 AR027442 A1 AR 027442A1
Authority
AR
Argentina
Prior art keywords
thyroid
neurotoxin
botulinum toxin
administered
hyperthyroidism
Prior art date
Application number
ARP010100698A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR027442A1 publication Critical patent/AR027442A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP010100698A 2000-02-15 2001-02-15 Uso de una neurotoxina para preparar una composicion farmaceutica para el tratamiento de un desorden tiroide AR027442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/504,538 US6524580B1 (en) 2000-02-15 2000-02-15 Method for treating thyroid disorders

Publications (1)

Publication Number Publication Date
AR027442A1 true AR027442A1 (es) 2003-03-26

Family

ID=24006701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100698A AR027442A1 (es) 2000-02-15 2001-02-15 Uso de una neurotoxina para preparar una composicion farmaceutica para el tratamiento de un desorden tiroide

Country Status (10)

Country Link
US (6) US6524580B1 (https=)
EP (1) EP1253933B1 (https=)
JP (2) JP2003530320A (https=)
AR (1) AR027442A1 (https=)
AT (1) ATE245032T1 (https=)
AU (1) AU2001238369A1 (https=)
DE (1) DE60100473T2 (https=)
ES (1) ES2199209T3 (https=)
TW (1) TWI283177B (https=)
WO (1) WO2001060396A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US8563257B2 (en) * 2000-03-30 2013-10-22 Diagnostic Hybrids, Inc. Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US8293879B2 (en) 2000-03-30 2012-10-23 Diagnostic Hybrids, Inc. Methods of using chimeric receptors to identify autoimmune disease
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7178059B2 (en) * 2003-05-07 2007-02-13 Egenera, Inc. Disaster recovery for processing resources using configurable deployment platform
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8137924B2 (en) * 2003-12-19 2012-03-20 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
RU2446791C2 (ru) * 2009-06-18 2012-04-10 Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" Способ этаноловой склеротерапии кистозно-трансформированных узлов щитовидной железы
AU2010315396B2 (en) 2009-10-27 2016-05-05 Nuvaira, Inc Delivery devices with coolable energy emitting assemblies
JP6000851B2 (ja) 2009-11-11 2016-10-05 ホライラ， インコーポレイテッド 組織治療および狭窄制御のためのシステム、装置、および方法
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9011323B2 (en) * 2010-10-08 2015-04-21 Invuity, Inc. Method and apparatus for soft tissue retraction
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
AU2022252296A1 (en) 2021-03-30 2023-09-21 Tulavi Therapeutics, Inc. Methods and compositions for the ablation of nerves
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5786348A (en) * 1991-01-08 1998-07-28 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
ES2107051T3 (es) 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP1011695B2 (en) 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6022554A (en) 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6432723B1 (en) * 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6432623B1 (en) * 2001-04-27 2002-08-13 Eastman Kodak Company Method for processing a photographic element comprising a simultaneously coated protective overcoat

Also Published As

Publication number Publication date
ES2199209T3 (es) 2004-02-16
TWI283177B (en) 2007-07-01
US6743424B1 (en) 2004-06-01
US6524580B1 (en) 2003-02-25
JP2012207030A (ja) 2012-10-25
WO2001060396A2 (en) 2001-08-23
WO2001060396A3 (en) 2002-03-14
AU2001238369A1 (en) 2001-08-27
US6447785B1 (en) 2002-09-10
US6716427B1 (en) 2004-04-06
JP2003530320A (ja) 2003-10-14
US6740321B1 (en) 2004-05-25
ATE245032T1 (de) 2003-08-15
US6585970B1 (en) 2003-07-01
DE60100473T2 (de) 2004-04-15
DE60100473D1 (de) 2003-08-21
EP1253933A2 (en) 2002-11-06
EP1253933B1 (en) 2003-07-16

Similar Documents

Publication Publication Date Title
AR027442A1 (es) Uso de una neurotoxina para preparar una composicion farmaceutica para el tratamiento de un desorden tiroide
ES2238969T3 (es) Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
CN1874784B (zh) 用肉毒杆菌毒素治疗鼻窦炎相关的慢性面部疼痛及头痛
DE69432179D1 (de) Eine formulierung des gerinnungsfaktors viii
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
KR910005858A (ko) 지방산 요법
RU2640001C1 (ru) Способ лечения дегенеративно-дистрофических заболеваний позвоночника (дорсопатий)
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
Shallenberger et al. Prolozone™–regenerating joints and eliminating pain
Harrison Advanced Cancer of the Head and Neck: Treatment by a Combination of Intra-Arterial Infusion and Systemic Chemotherapy
US20240189382A1 (en) Formula for inhibiting aging regeneration repair
Arlen Combined radiation-methotrexate therapy in preoperative management of carcinoma of the head and neck
RU2297233C1 (ru) Способ лечения глоссалгии
RU2088247C1 (ru) Способ повышения эффективности лучевой терапии
RU2071324C1 (ru) Способ лечения эмфиземы легких или пневмосклероза
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
Abraham Calcium phosphate mouth rinse for preventing oral mucositis
EA200100223A3 (ru) Воднодисперсная лекарственная форма ивермектина для лечения экто- и эндопаразитозов
RU2242989C2 (ru) Способ лечения дисциркуляторной энцефалопатии
ZHUANG et al. Efficacy and safety of modified Chaihu Jia Longgu Muli tang in treating mild to moderate essential hypertension complicated with depression and liver-yang hyperactivity syndrome
CUI et al. Clinical study on Kangliu Pill combined with conventional therapy in the treatment of malignant gliomas
RU2227017C2 (ru) Способ лечения хронических рецидивирующих трещин губ и сочетаний хронических рецидивирующих трещин губ с эксфолиативным или атопическим хейлитами
Pasquier et al. Radio-induced lesion in normal tissues

Legal Events

Date Code Title Description
FB Suspension of granting procedure